- Muschen, Markus;
- Buchner, M;
- Park, E;
- Geng, H;
- Klemm, L;
- Flach, J;
- Passegué, E;
- Schjerven, H;
- Melnick, A;
- Paietta, E;
- Kopanja, D
© 2015 Macmillan Publishers Limited.Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a candidate responsible for an aggressive clinical cou
